Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-07-17
2010-10-26
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S323000, C544S324000, C544S325000
Reexamination Certificate
active
07820687
ABSTRACT:
Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4837028 (1989-06-01), Allen et al.
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5023252 (1991-06-01), Hseih et al.
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6436904 (2002-08-01), Ashwell et al.
patent: 6479492 (2002-11-01), Konradi et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 6544994 (2003-04-01), Rabelink et al.
patent: 6545003 (2003-04-01), Grant et al.
patent: 6689781 (2004-02-01), Konradi et al.
patent: 6794506 (2004-09-01), Konradi et al.
patent: 6903088 (2005-06-01), Konradi et al.
patent: 6911439 (2005-06-01), Konradi et al.
patent: 7005433 (2006-02-01), Konradi et al.
patent: 7008949 (2006-03-01), Konradi et al.
patent: 7026328 (2006-04-01), Konradi et al.
patent: 7049306 (2006-05-01), Konradi et al.
patent: 7135477 (2006-11-01), Konradi et al.
patent: 7335663 (2008-02-01), Konradi et al.
patent: 7378529 (2008-05-01), Konradi et al.
patent: 7427628 (2008-09-01), Konradi et al.
patent: 7452912 (2008-11-01), Grant et al.
patent: 7579466 (2009-08-01), Smith et al.
patent: 2005/0203093 (2005-09-01), Konradi et al.
patent: 2005/0261293 (2005-11-01), Konradi et al.
patent: 2006/0013799 (2006-01-01), Konradi et al.
patent: 2007/0099921 (2007-05-01), Konradi et al.
patent: 2007/0129390 (2007-06-01), Semko et al.
patent: 2007/0142416 (2007-06-01), Semko et al.
patent: 2008/0058357 (2008-03-01), Smith et al.
patent: 2241149 (1997-07-01), None
patent: 2259224 (1998-01-01), None
patent: 2359115 (2000-07-01), None
patent: 195 36 891 (1997-04-01), None
patent: 265 56 36 (1997-06-01), None
patent: 195 48 709 (1997-07-01), None
patent: 196 54 483 (1998-01-01), None
patent: 197 13 000 (1998-10-01), None
patent: 116494 (1984-08-01), None
patent: 0 147 211 (1985-07-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: 1500063 (1978-02-01), None
patent: 169926 (1977-02-01), None
patent: 59212480 (1984-12-01), None
patent: WO 91/05038 (1991-04-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 93/24154 (1993-12-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/32383 (1996-10-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 97/48726 (1997-12-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/22430 (1998-05-01), None
patent: WO 98/33783 (1998-08-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 00/31067 (2000-06-01), None
patent: WO 00/43369 (2000-07-01), None
patent: WO 00/43371 (2000-07-01), None
patent: WO 00/43372 (2000-07-01), None
patent: WO 02/08201 (2002-01-01), None
patent: WO 03/099231 (2003-12-01), None
patent: WO 03/099809 (2003-12-01), None
patent: WO 2005/111020 (2005-11-01), None
patent: WO 2007/041270 (2007-04-01), None
patent: WO 2007/041324 (2007-04-01), None
patent: WO 2007/101165 (2007-09-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Tarkowski et al. Int. Arch. Allergy Immunol.121(1) 25-33, 2000.
Grayson et al., J. Exp. Med., 188(11), 2187-2191, 1998.
Tilley et al., Drugs of the Future, 26(10), 985-998, 2001.
U.S. Appl. No. 12/645,154, filed Dec. 22, 2009, Konradi et al.
U.S. Appl. No. 12/637,719, filed Dec. 14, 2009, Konradi et al.
U.S. Appl. No. 12/579,828, filed Oct. 15, 2009, Semko et al.
Abraham, W.M., et al. “α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93: 776-787 (1994).
Abraham, et al., “Blockade of Late-phase Airway Responses and Airway Hyperresponsiveness in allergic Sheep with a Small-molecule Peptide Inhibitor of VLA-4,”Am J Resper Crit Care Med156:696-703 (1997).
Advani, S.B., et al. “Potential Antineoplastic Agents: N-(2-Benzoxazolyl)amino Acid Esters.”J. of Pharm. Sci. 57(10): 1693-1696 (1968).
Anderson, et al., “Acute kidney graft rejection,”APMIS102, 23-37 (1994).
Anderson, et al., “Process Development of 5-Fluoro-3-[3-[4-(5-methoxy-4 pyrimidinyl)-1 piperazinyl]propyl]-1H-indole Dihydrochloride,”Org Proc Res Devel1:300-310 (1997).
Balaban, I., “An Investigation into the Formation of 4(5)-Aminoglyoxalines,”J. chem.. soc. Part 1:1-268-273 (1930).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Banker, G.S. et al., “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, pp. 451-596 (1996).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med. 177:57-68 (1993).
Baron, J.L., et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Belka et al., “Radiation induced CNS toxicity—Molecular and cellular mechanism”Br. J. Cancer85:1233-1239 (2001).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated
Konradi Andrei W.
Semko Chris
Smith Jenifer
Xu Ying-Zi
Balasubramanian Venkataraman
Elan Pharmaceuticals Inc.
Swiss Tanner, P.C.
LandOfFree
Pyrimidinyl sulfonamide compounds which inhibit leukocyte... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidinyl sulfonamide compounds which inhibit leukocyte..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidinyl sulfonamide compounds which inhibit leukocyte... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228049